peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Financial documents

Analysts and consensus

Analyst Coverage

BankAnalystEmailPhoneLocation
SEBChristopher Uhdechristopher.uhde@seb.se+46 876 385 53Stockholm
RBCZoe KaramanoliZoe.Karamanoli@rbccm.com+44 7834 765119London
ABG Sundal CollierAdam Karlssonadam.karlsson@abgsc.se+46 8 566 286 91Stockholm
RedeyeJohan Unnerusjohan.unnerus@redeye.se+46 724 023 385Stockholm
KempenJacob Mekhael Jacob.Mekhael@kempen.com+31 6 8367 7236Amsterdam
CarnegieErik Hultgårderik.hultgard@carnegie.se+46 (0)8 5886 9237Stockholm
Intron Health ResearchNaresh ChouhanNaresh@IntronHealthResearch.com+44 7939 224 322London
Ökonomisk UgebrevLars Hatholthatholt@outlook.com+45 22 23 78 15Copenhagen
Danske BankCaroline Banércaroline.baner@danskebank.se+46 76 721 66 94Stockholm
Erik Penser BankLudvig Svenssonludvig.svensson@penser.se+46 (0) 84 638 059Stockholm
H.C. Wainwright & Co.Douglas Tsaodtsao@hcwresearch.com+1 212 916 3968New York City
Bryan, Garnier & Co.Ingrid Gafanhaoigafanhao@bryangarnier.comParis

Analyst Consensus

   Patient uptake, EURevenue, SEKmEBIT, SEKmOperating Cash Flow, SEKmCash position, SEKmPotential capital increase, SEKm
Consensus estimatesPrice target, SEKWACCQ2'22eFY'22e FY'23eFY'24eQ2'22eFY'22e FY'23eFY'24eQ2'22eFY'22e FY'23eFY'24eQ2'22eFY'22e FY'23eFY'24eQ2'22eFY'22e FY'23eFY'24eQ2'22eFY'22e FY'23eFY'24e
Average23611.0%426 5110818 98182331-154-611 -669-670-107 -583 -646-674533 408413-54690  942 
Median23011.0%426 5910518105 194328-160-617-645-581-107 -577-619-596533 347429195 690  1,000
High41015.0%6356619526128 280543-127-455 -489-320-83 -454-461-296628 1,1221,3185350880 1,000
Low1207.6%315223010 537296-180-755 -1,072-1,424-130 -726-1,105-1,118437 162-285-9220500 825
Number of contributions111068887 1010107 10101021010102 107700 4
Recommendation
Buy12
Hold 0
 Sell 0

This is a company-collected consensus prepared with consolidated estimates submitted from research analysts covering the Hansa Biopharma stock. The consensus provided is based on a collection of estimates done on a quarterly basis. Any opinions, forecasts, estimates, projections or predictions regarding Hansa Biopharma’s performance made by the analysts (and, therefore, the consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of Hansa Biopharma or its management. Hansa Biopharma does not by providing these estimates imply, and expressly disclaims, any endorsement of or concurrence with any information, estimates, forecasts, opinions, conclusions or recommendations made or provided by such analysts. Hansa Biopharma assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.